<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Disopyramide: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i119.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i119.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i119.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i116.htm">Anti-arrhythmics</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i118.htm" title="Previous: Amiodarone">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i120.htm" title="Next: Flecainide">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i119">Disopyramide</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Disopyramide</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i551.htm">Acetazolamide</a></td><td class="cBV"><b>increased cardiac toxicity with  disopyramide if hypokalaemia occurs with acetazolamide </b></td><td></td></tr><tr><td><a href="41001i118.htm" name="_118">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i809.htm">Amisulpride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with amisulpride—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i241.htm" name="_241">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with tricyclics </b></td><td></td></tr><tr><td><a href="41001i342.htm" name="_342">Antimuscarinics</a></td><td>increased risk of antimuscarinic side-effects when  disopyramide given with antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i1168.htm" name="_1168">Arsenic Trioxide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with arsenic trioxide </b></td><td></td></tr><tr><td><a href="41001i937.htm" name="_937">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  disopyramide advised by manufacturer of artemether/lumefantrine (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1009.htm" name="_1009">Atomoxetine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with atomoxetine </b></td><td></td></tr><tr><td><a href="41001i167.htm">Azithromycin</a></td><td class="cBV"><b>plasma concentration of  disopyramide possibly increased by azithromycin (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of  disopyramide possibly increased by clarithromycin (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i539.htm">Diuretics, Loop</a></td><td class="cBV"><b>increased cardiac toxicity with  disopyramide if hypokalaemia occurs with loop diuretics </b></td><td></td></tr><tr><td><a href="41001i525.htm">Diuretics, Thiazide and related</a></td><td class="cBV"><b>increased cardiac toxicity with  disopyramide if hypokalaemia occurs with thiazides and related diuretics </b></td><td></td></tr><tr><td><a href="41001i1176.htm" name="_1176">Dronedarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1152.htm" name="_1152">Droperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with droperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>plasma concentration of  disopyramide increased by erythromycin (increased risk of toxicity)</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1202.htm" name="_1202">Fingolimod</a></td><td class="cBV"><b>possible increased risk of bradycardia when  disopyramide given with fingolimod </b></td><td></td></tr><tr><td><a href="41001i271.htm" name="_271">Gliclazide</a></td><td> disopyramide possibly enhances hypoglycaemic effect of gliclazide </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  disopyramide given with haloperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i265.htm" name="_265">Insulin</a></td><td> disopyramide possibly enhances hypoglycaemic effect of insulin </td><td></td></tr><tr><td><a href="41001i302.htm" name="_302">Itraconazole</a></td><td class="cBV"><b>avoidance of  disopyramide advised by manufacturer of itraconazole </b></td><td></td></tr><tr><td><a href="41001i1050.htm" name="_1050">Ivabradine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with ivabradine </b></td><td></td></tr><tr><td><a href="41001i298.htm" name="_298">Ketoconazole</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with ketoconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i267.htm" name="_267">Metformin</a></td><td> disopyramide possibly enhances hypoglycaemic effect of metformin </td><td></td></tr><tr><td><a href="41001i841.htm" name="_841">Mizolastine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i973.htm" name="_973">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i631.htm" name="_631">Nitrates</a></td><td> disopyramide reduces effects of sublingual tablets of nitrates (failure to dissolve under tongue owing to dry mouth)</td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  disopyramide given with pentamidine isetionate </b></td><td></td></tr><tr><td><a href="41001i437.htm" name="_437">Phenobarbital</a></td><td>metabolism of  disopyramide accelerated by phenobarbital (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i373.htm" name="_373">Phenothiazines</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with phenothiazines </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  disopyramide reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i369.htm" name="_369">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1147.htm" name="_1147">Ranolazine</a></td><td class="cBV"><b>avoidance of  disopyramide advised by manufacturer of ranolazine </b></td><td></td></tr><tr><td><a href="41001i199.htm" name="_199">Rifamycins</a></td><td class="cBV"><b>metabolism of  disopyramide accelerated by rifamycins (reduced plasma concentration)</b></td><td>Interactions do not apply to rifaximin</td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  disopyramide possibly increased by ritonavir (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i791.htm" name="_791">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td>manufacturer of  disopyramide advises avoid concomitant use with sildenafil (risk of ventricular arrhythmias)</td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with sotalol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i371.htm" name="_371">Sulpiride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with sulpiride </b></td><td></td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td>manufacturer of  disopyramide advises avoid concomitant use with tadalafil (risk of ventricular arrhythmias)</td><td></td></tr><tr><td><a href="41001i1216.htm" name="_1216">Telaprevir</a></td><td class="cBV"><b>avoidance of  disopyramide advised by manufacturer of telaprevir (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i850.htm" name="_850">Tolterodine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with tolterodine </b></td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td>manufacturer of  disopyramide advises avoid concomitant use with vardenafil (risk of ventricular arrhythmias)</td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b>increased risk of myocardial depression and asystole when  disopyramide given with verapamil </b></td><td></td></tr><tr><td><a href="41001i222.htm" name="_222">Warfarin</a></td><td> disopyramide may enhance or reduce anticoagulant effect of warfarin </td><td></td></tr><tr><td><a href="41001i390.htm" name="_390">Zuclopenthixol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with zuclopenthixol—avoid concomitant use</b></td><td></td></tr></tbody></table><p>Disopyramide belongs to <b>Anti-arrhythmics</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i116.htm">Anti-arrhythmics</a></td><td class="cBV"><b>increased myocardial depression when  anti-arrhythmics given with other anti-arrhythmics </b></td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  anti-arrhythmics that prolong the QT interval given with antipsychotics that prolong the QT interval</b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td class="cBV"><b>increased myocardial depression when  anti-arrhythmics given with beta-blockers </b></td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i54.htm">Bupivacaine</a></td><td>increased myocardial depression when  anti-arrhythmics given with bupivacaine </td><td></td></tr><tr><td><a href="41001i906.htm">Levobupivacaine</a></td><td>increased myocardial depression when  anti-arrhythmics given with levobupivacaine </td><td></td></tr><tr><td><a href="41001i873.htm">Prilocaine</a></td><td>increased myocardial depression when  anti-arrhythmics given with prilocaine </td><td></td></tr><tr><td><a href="41001i888.htm">Ropivacaine</a></td><td>increased myocardial depression when  anti-arrhythmics given with ropivacaine </td><td></td></tr></tbody></table></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i118.htm">Previous: Amiodarone</a> | <a class="top" href="41001i119.htm#">Top</a> | <a accesskey="]" href="41001i120.htm">Next: Flecainide</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>